Breast Cancer Update Home - Oncology Leader Commentary

Home: Oncology Leader Commentary: C Kent Osbourne, MD

Click on the topic below for comments by Dr C Kent Osborne to comment on. You will also find links to related articles and clinical trials.

Problems with estrogen receptor assays
Cut-off for ER-positivity
Receptor assays in metastatic disease
Mechanism of action of Faslodex
Receptor downregulation and Faslodex
Faslodex effects in the laboratory
Randomized trials comparing Faslodex to Arimidex
Tolerability of Faslodex
Other trials of Faslodex
Future Clinical role of Faslodex
Intramuscular injection of Faslodex
Clinical trials of adjuvant Faslodex
Management of DCIS
Future trials of Faslodex plus estrogen

Home

Patrick I. Borgen, MD

Aman Buzdar, MD

Nancy E. Davidson, MD

J. Michael Dixon, MD

Armando Giuliano, MD

I. Craig Henderson, MD

David Krag, MD

Gershon Locker, MD

Charles Loprinzi, MD

Richard Margolese, MD

Monica Morrow, MD

C Kent Osborne, MD

Sir Richard Peto, FRS

Kathy I. Pritchard, MD

John F. Robertson, MD,FRCS

Andrew D. Seidman, MD

George W. Sledge, MD

Home · Contact us

Terms of use and general disclaimer